Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200

Benzinga · 2d ago
Guggenheim analyst Brad Canino maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $175 to $200.